GO
Loading...

Enter multiple symbols separated by commas

Mergers and Acquisitions Takeover Bids

More

  • Does QE3 Really Matter? Monday, 10 Sep 2012 | 8:03 AM ET
    Does QE3 Really Matter?

    "Ultimately, I don't think lower rates make that much difference anymore," says Dinakar Singh, TPG-Axon Capital CEO, sharing his thoughts on additional Fed easing.

  • Featured Speaker - Henry R. Kravis Monday, 16 Jul 2012 | 12:04 PM ET
    Henry R. Kravis, Co-Chairman and Co-CEO, KKR

    The co-founder of the trailblazing private-equity firm Kohlberg Kravis Roberts is actively involved in managing the firm famous for its leveraged buyout of RJR Nabisco 25 years ago.

  • Faber Report: GSK's Acquires Human Genome Science Monday, 16 Jul 2012 | 9:42 AM ET
    Faber Report: GSK's Acquires Human Genome Science

    CNBC's David Faber reports the latest details on GlaxoSmithKline's takeover bid for Human Genome Science.

  • Five Stocks Ripe for Takeovers? Tuesday, 10 Jul 2012 | 8:49 AM ET
    big_vs_little2_200.jpg

    Here are five companies that could be bought, according to analyst Ken Hackel of CT Capital, best known for his book, “Security Valuation and Risk Analysis.”

  • $7.1 Billion Pharma Deal Monday, 2 Jul 2012 | 1:11 PM ET
    $7.1 Billion Pharma Deal

    CNBC's Scott Cohn reports on what the Justice Department calls the biggest health care fraud settlement in U.S. history; and CNBC's Seema Mody reports on the details of Bristol-Myers' plans to buy Amylin.

  • Deal Brewing Between Grupo Modelo and Anheuser Monday, 25 Jun 2012 | 11:50 AM ET
    Deal Brewing Between Grupo Modelo and Anheuser

    CNBC's Kayla Tausche reports Grupo Modelo has confirmed it is in talks on expanding its relationship with Anheuser-Busch.

  • What's Next for Carl Icahn? Monday, 30 Apr 2012 | 4:14 PM ET
    What's Next for Carl Icahn?

    CNBC's David Faber speaks to activist investor Carl Icahn regarding how much cash he has available to invest and whether Chesapeake Energy is undervalued.

  • Human Genome Rejects GlaxoSmithKline's Bid Thursday, 19 Apr 2012 | 12:41 PM ET
    Human Genome Rejects GlaxoSmithKline's Bid

    Human Genome Sciences rejected the $2.6 billion unsolicited takeover bid from GlaxoSmithKline, reports CNBC's Herb Greenberg.

  • Illumina Plays Offense & Final Trade Tuesday, 17 Apr 2012 | 12:55 PM ET
    Illumina Plays Offense & Final Trade

    CNBC's Kayla Tausche reports on Illumina playing offense against Roche's hostile takeover bid, and the FMHR crew share their final trades of the hour.

  • Faber Report: Illumina Tuesday, 17 Apr 2012 | 9:42 AM ET
    Faber Report: Illumina

    CNBC's David Faber reports the latest details on Illumina's recommendation to shareholders to reject Roche's takeover offer.

  • No Huddle Offense: RIMM & YHOO, Takeover Targets or Turnarounds?

    Mad Money host Jim Cramer shares his final thoughts on the future of tech giants, Research in Motion and Yahoo.

  • Avon for Sale? Monday, 2 Apr 2012 | 5:17 PM ET
    Avon for Sale?

    The Fast Money traders weigh in on how to play unusual options activity in Avon's shares on Monday.

  • Groupon Revises Q4 & Full Year Monday, 2 Apr 2012 | 3:09 PM ET
    Groupon Revises Q4 & Full Year

    CNBC's Brian Shactman breaks down today's big movers including two downgrades at Stifel Nicolaus, and Avon's rejection of a takeover bid from Coty.

  • Finerman's Fine Print: Illumina Rejects Roche Wednesday, 8 Feb 2012 | 5:29 PM ET
    Finerman's Fine Print: Illumina Rejects Roche

    Karen Finerman, Metropolitan Capital Advisors, and Fast Money trader, provides insight on what's next for Illumina, on the heels its recent rejection of Roche's offer.

  • Ways to Win In This Market Wednesday, 25 Jan 2012 | 6:43 PM ET

    Cramer ticks off the many winning trades today.

  • Roche Makes $5.7B Bid for Illumina Wednesday, 25 Jan 2012 | 5:21 PM ET
    Roche Makes $5.7B Bid for Illumina

    Keith Moore, MKM Partners, discusses how to play Roche's hostile bid for gene sequencer, Illumin, saying ILMN is likely to fight the takeover. Also an update on SanDisk's earnings, with the Fast Money crew.

  • Finerman's Fine Print: Roche Hostility Wednesday, 25 Jan 2012 | 5:18 PM ET
    Finerman's Fine Print: Roche Hostility

    Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.

  • Is Netflix a Takeover Target? Wednesday, 4 Jan 2012 | 5:00 PM ET
    Is Netflix a Takeover Target?

    Is Netflix a possible takeover candidate by Yahoo? Gene Munster, Piper Jaffray, and the Fast Money traders, weigh in on the rumor, and the possible play on the stocks, and options activity. Also a paid to wait options strategy on Yahoo, with Pete Najarian, Fast Money trader.

  • RIMM Turns Down Takeover Overtures Tuesday, 20 Dec 2011 | 5:28 PM ET
    RIMM Turns Down Takeover Overtures

    The Fast Money traders weigh in on possible suitors for RIM, including, Amazon. Also, the play on Jefferies, as shares surge more than 20% on better-than-expected earnings.

  • Finerman's Fine Print: MLM Gets Hostile Monday, 12 Dec 2011 | 5:40 PM ET
    Finerman's Fine Print: MLM Gets Hostile

    Fast Money trader, Karen Finerman takes a closer look at the hostile takeover attempt by Martin Marietta Materials for Vulcan Materials.